Stockscreener 앱 받기
1.43
1.42%
0.02
시간 외 거래:
1.43
전일 마감가:
$1.41
열려 있는:
$1.41
하루 거래량:
264.17K
Relative Volume:
0.88
시가총액:
$53.14M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-0.6413
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
+14.40%
1개월 성능:
+33.64%
6개월 성능:
-60.06%
1년 성능:
-57.31%
1일 변동 폭
$1.40
$1.48
1주일 범위
$1.2601
$1.48
52주 변동 폭
$0.89
$4.29
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.43 | 53.14M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo Finance
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News
Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus
Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com
Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX
Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com
B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com
Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com India
Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com Nigeria
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com
Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com
Cathie Wood's Ark Invest Loads Up On Amazon Amid Over 20% Decline In A Year: Offloads UiPath, Roblox - Benzinga
Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals
Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech
Repare Therapeutics Appoints Steve Forte CEO - citybiz
Repare Therapeutics appoints CFO as new CEO - MSN
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener
Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks
Repare Therapeutics Names Forte as President, CEO - MarketWatch
Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks
Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Stocks in play: BMO - The Globe and Mail
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock By Investing.com - Investing.com South Africa
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Repare Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Repare Therapeutics stock hits 52-week low at $1.05 - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% of staff; Empress halves workforce - Fierce Biotech
Media AdvisoryBMO Group Head, Commercial Bank, Nadim Hirji to Speak at the National Bank Financial Services Conference - The Globe and Mail
Repare therapeutics’ chief medical officer sells shares for $4,099 By Investing.com - Investing.com Australia
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Repare therapeutics’ chief scientific officer sells $6,396 in shares - Investing.com India
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):